+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia



Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia



Cancer 106(4): 839-847



Different diagnostic methods add information to define complete remission (CR) in patients with acute myeloid leukemia (AML). The detection of minimal residual disease (MRD) for predicting prognosis and for therapeutic planning still are under discussion. The authors studied 216 patients with AML at the time of initial diagnosis and during follow-up and correlated cytomorphology, interphase fluorescence in situ hybridization (FISH), and flow cytometry results to evaluate response status. They further tested the prognostic impact of those results, especially in patients who achieved a morphologic CR. Interphase FISH was found to be correlated significantly with the clinical course at the time of complete cytomorphologic remission and was more reliable than morphology for defining CR. Furthermore, interphase FISH was correlated with immunophenotyping results at all times during follow-up. The current results indicated that interphase FISH may be used as a valid MRD parameter in patients with AML. Multiparameter immunophenotyping for MRD also was correlated strongly with the clinical course, and the authors suggest integrating such immunophenotyping into the routine diagnostic panel at the time of diagnosis and during the clinical course in patients with AML.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012057315

Download citation: RISBibTeXText

PMID: 16419072

DOI: 10.1002/cncr.21665


Related references

The definition of complete remission in acute myeloid leukemia needs to be modernized A study on 268 patients analyzed at 569 timepoints during follow-up by cytomorphology and interphase FISH as well as by immunophenotyping and PCR. Blood 102(11): 876a, November 16, 2003

Detection of bcr/abl gene rearrangements patterns by interphase fluorescence in situ hybridization in chronic myeloid leukemia , acute lymphoblastic leukemia and acute myeloid leukemia. Cytometry Supplement (11): 104, 2002

Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission. Blood 89(9): 3330-3334, 1997

Interphase fluorescence in situ hybridization reveals minimal residual disease at the end of remission and may indicate return of the diagnostic clone in relapse of acute lymphoblastic leukemia but not of acute nonlymphoblastic leukemia. Onkologie 18(SUPPL 2): 90, 1995

A new classification of interphase nuclei based on spatial organizations of chromosome 8 and 21 for t(8;21) (q22;q22) acute myeloid leukemia by three-dimensional fluorescence in situ hybridization. Leukemia Research 39(12): 1414-1420, 2016

Hidden monosomy 7 in acute myeloid leukemia and myelodysplastic syndrome detected by interphase fluorescence in situ hybridization. Leukemia Research. 20(9): 709-716, 1996

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 114(24): 4939-4943, 2010

Validation of an interphase fluorescence in situ hybridization approach for the detection of MLL gene rearrangements and of the MLL/AF9 fusion in acute myeloid leukemia. Haematologica 91(3): 381-385, 2006

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica 100(6): 780-785, 2016

Combined immunophenotyping and fluorescence in situ hybridization with chromosome-specific DNA probes allows quantification and differentiation of ex vivo generated dendritic cells, leukemia-derived dendritic cells and clonal leukemic cells in patients with acute myeloid leukemia. Leukemia and Lymphoma 54(6): 1297-1308, 2013

Identical cytogenetic clones and clonal evolution in pediatric monozygotic twins with acute myeloid leukemia: presymptomatic disease detection by interphase fluorescence in situ hybridization and review of the literature. Journal of Pediatric Hematology/Oncology 20(3): 264-267, 1998

Hypermetaphase fluorescence in situ hybridization is a suitable method to monitor residual disease in patients with acute myeloid leukemia. Annals of Hematology 77(SUPPL 2): S111, 1998

A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia. Genes, Chromosomes and Cancer 56(8): 632-638, 2017

Limited Utility of Fluorescence In Situ Hybridization for Recurrent Abnormalities in Acute Myeloid Leukemia at Diagnosis and Follow-up. American Journal of Clinical Pathology 149(5): 418-424, 2018

Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival. Postepy Higieny i Medycyny Doswiadczalnej 67: 553-559, 2013